Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Sep;69(9):5300–5303. doi: 10.1128/jvi.69.9.5300-5303.1995

Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes.

A Morrione 1, T DeAngelis 1, R Baserga 1
PMCID: PMC189367  PMID: 7636972

Abstract

Mouse embryo cells with a targeted disruption of the insulin-like growth factor I receptor (IGF-IR) genes (R- cells) are refractory to transformation by the simian virus 40 large T antigen and/or an activated and overexpressed Ras, both of which readily transform cells from wild-type littermate embryos and other 3T3-like cells. R- cells are also refractory to transformation induced by overexpressed epidermal growth factor receptor and platelet-derived growth factor receptor beta. Since the platelet-derived growth factor receptor beta is required for transformation by bovine papillomavirus, we inquired whether the IGF-IR was also required for transformation by bovine papillomavirus E5 oncoprotein. We show here that R- cells are refractory to transformation by E5; reintroduction into R- cells of a human IGF-IR restores the susceptibility to transformation.

Full Text

The Full Text of this article is available as a PDF (394.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arteaga C. L., Osborne C. K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15;49(22):6237–6241. [PubMed] [Google Scholar]
  2. Baker J., Liu J. P., Robertson E. J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993 Oct 8;75(1):73–82. [PubMed] [Google Scholar]
  3. Baserga R. Oncogenes and the strategy of growth factors. Cell. 1994 Dec 16;79(6):927–930. doi: 10.1016/0092-8674(94)90023-x. [DOI] [PubMed] [Google Scholar]
  4. Baserga R., Sell C., Porcu P., Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif. 1994 Feb;27(2):63–71. doi: 10.1111/j.1365-2184.1994.tb01406.x. [DOI] [PubMed] [Google Scholar]
  5. Burnett S., Jareborg N., DiMaio D. Localization of bovine papillomavirus type 1 E5 protein to transformed basal keratinocytes and permissive differentiated cells in fibropapilloma tissue. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5665–5669. doi: 10.1073/pnas.89.12.5665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Campbell K. S., Ogris E., Burke B., Su W., Auger K. R., Druker B. J., Schaffhausen B. S., Roberts T. M., Pallas D. C. Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6344–6348. doi: 10.1073/pnas.91.14.6344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994 Jun 2;369(6479):414–418. doi: 10.1038/369414a0. [DOI] [PubMed] [Google Scholar]
  8. Clemmons D. R. Multiple hormones stimulate the production of somatomedin by cultured human fibroblasts. J Clin Endocrinol Metab. 1984 May;58(5):850–856. doi: 10.1210/jcem-58-5-850. [DOI] [PubMed] [Google Scholar]
  9. Clemmons D. R., Shaw D. S. Variables controlling somatomedin production by cultured human fibroblasts. J Cell Physiol. 1983 May;115(2):137–142. doi: 10.1002/jcp.1041150206. [DOI] [PubMed] [Google Scholar]
  10. Coppola D., Ferber A., Miura M., Sell C., D'Ambrosio C., Rubin R., Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 1994 Jul;14(7):4588–4595. doi: 10.1128/mcb.14.7.4588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DeAngelis T., Ferber A., Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol. 1995 Jul;164(1):214–221. doi: 10.1002/jcp.1041640126. [DOI] [PubMed] [Google Scholar]
  12. Dilworth S. M., Brewster C. E., Jones M. D., Lanfrancone L., Pelicci G., Pelicci P. G. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature. 1994 Jan 6;367(6458):87–90. doi: 10.1038/367087a0. [DOI] [PubMed] [Google Scholar]
  13. Fantl W. J., Escobedo J. A., Williams L. T. Mutations of the platelet-derived growth factor receptor that cause a loss of ligand-induced conformational change, subtle changes in kinase activity, and impaired ability to stimulate DNA synthesis. Mol Cell Biol. 1989 Oct;9(10):4473–4478. doi: 10.1128/mcb.9.10.4473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kaleko M., Rutter W. J., Miller A. D. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990 Feb;10(2):464–473. doi: 10.1128/mcb.10.2.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kato H., Faria T. N., Stannard B., Roberts C. T., Jr, LeRoith D. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3). J Biol Chem. 1993 Feb 5;268(4):2655–2661. [PubMed] [Google Scholar]
  16. Li S., Ferber A., Miura M., Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. J Biol Chem. 1994 Dec 23;269(51):32558–32564. [PubMed] [Google Scholar]
  17. Liu D., Zong C. S., Wang L. H. Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions. J Virol. 1993 Nov;67(11):6835–6840. doi: 10.1128/jvi.67.11.6835-6840.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liu J. P., Baker J., Perkins A. S., Robertson E. J., Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993 Oct 8;75(1):59–72. [PubMed] [Google Scholar]
  19. McCubrey J. A., Steelman L. S., Mayo M. W., Algate P. A., Dellow R. A., Kaleko M. Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism. Blood. 1991 Aug 15;78(4):921–929. [PubMed] [Google Scholar]
  20. Meyer A. N., Xu Y. F., Webster M. K., Smith A. E., Donoghue D. J. Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4634–4638. doi: 10.1073/pnas.91.11.4634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Miura M., Li S. W., Dumenil G., Baserga R. Platelet-derived growth factor-induced expression of messenger RNA for the proliferating cell nuclear antigen requires a functional receptor for the insulin-like growth factor I. Cancer Res. 1994 May 1;54(9):2472–2477. [PubMed] [Google Scholar]
  22. Nilson L. A., DiMaio D. Platelet-derived growth factor receptor can mediate tumorigenic transformation by the bovine papillomavirus E5 protein. Mol Cell Biol. 1993 Jul;13(7):4137–4145. doi: 10.1128/mcb.13.7.4137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Petti L., DiMaio D. Specific interaction between the bovine papillomavirus E5 transforming protein and the beta receptor for platelet-derived growth factor in stably transformed and acutely transfected cells. J Virol. 1994 Jun;68(6):3582–3592. doi: 10.1128/jvi.68.6.3582-3592.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Petti L., Nilson L. A., DiMaio D. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J. 1991 Apr;10(4):845–855. doi: 10.1002/j.1460-2075.1991.tb08017.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pietrzkowski Z., Lammers R., Carpenter G., Soderquist A. M., Limardo M., Phillips P. D., Ullrich A., Baserga R. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Differ. 1992 Apr;3(4):199–205. [PubMed] [Google Scholar]
  26. Porcu P., Ferber A., Pietrzkowski Z., Roberts C. T., Adamo M., LeRoith D., Baserga R. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulinlike growth factor 1 with its receptor. Mol Cell Biol. 1992 Nov;12(11):5069–5077. doi: 10.1128/mcb.12.11.5069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Prager D., Li H. L., Asa S., Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2181–2185. doi: 10.1073/pnas.91.6.2181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994 Sep 15;54(18):4848–4850. [PubMed] [Google Scholar]
  29. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 1994 Apr 15;54(8):2218–2222. [PubMed] [Google Scholar]
  30. Rubini M., Werner H., Gandini E., Roberts C. T., Jr, LeRoith D., Baserga R. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene. Exp Cell Res. 1994 Apr;211(2):374–379. doi: 10.1006/excr.1994.1101. [DOI] [PubMed] [Google Scholar]
  31. Scher C. D., Shepard R. C., Antoniades H. N., Stiles C. D. Platelet-derived growth factor and the regulation of the mammalian fibroblast cell cycle. Biochim Biophys Acta. 1979 Aug 10;560(2):217–241. doi: 10.1016/0304-419x(79)90020-9. [DOI] [PubMed] [Google Scholar]
  32. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994 Jun;14(6):3604–3612. doi: 10.1128/mcb.14.6.3604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sell C., Rubini M., Rubin R., Liu J. P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11217–11221. doi: 10.1073/pnas.90.23.11217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stiles C. D., Capone G. T., Scher C. D., Antoniades H. N., Van Wyk J. J., Pledger W. J. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1279–1283. doi: 10.1073/pnas.76.3.1279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Trojan J., Blossey B. K., Johnson T. R., Rudin S. D., Tykocinski M., Ilan J., Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4874–4878. doi: 10.1073/pnas.89.11.4874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Trojan J., Johnson T. R., Rudin S. D., Ilan J., Tykocinski M. L., Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science. 1993 Jan 1;259(5091):94–97. doi: 10.1126/science.8418502. [DOI] [PubMed] [Google Scholar]
  37. Ullrich A., Gray A., Tam A. W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986 Oct;5(10):2503–2512. doi: 10.1002/j.1460-2075.1986.tb04528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Westermark B., Heldin C. H. Platelet-derived growth factor in autocrine transformation. Cancer Res. 1991 Oct 1;51(19):5087–5092. [PubMed] [Google Scholar]
  39. Yoakim M., Hou W., Songyang Z., Liu Y., Cantley L., Schaffhausen B. Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity. Mol Cell Biol. 1994 Sep;14(9):5929–5938. doi: 10.1128/mcb.14.9.5929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Yoshimura A., D'Andrea A. D., Lodish H. F. Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4139–4143. doi: 10.1073/pnas.87.11.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zon L. I., Moreau J. F., Koo J. W., Mathey-Prevot B., D'Andrea A. D. The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein. Mol Cell Biol. 1992 Jul;12(7):2949–2957. doi: 10.1128/mcb.12.7.2949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. de la Luna S., Soria I., Pulido D., Ortín J., Jiménez A. Efficient transformation of mammalian cells with constructs containing a puromycin-resistance marker. Gene. 1988;62(1):121–126. doi: 10.1016/0378-1119(88)90585-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES